Calamos Advisors’s West Pharmaceutical WST Stock Holding History

Calamos Advisors’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-89,884	Closed	-$7.63M	–	659
2016 Q4	$7.63M	Buy	+89,884	New	+$7.07M	0.06%	297

Other funds holding WST

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Calamos Advisors's WST Position: Q1 2017 in Review

Calamos Advisors sold out of West Pharmaceutical (WST) in Q1 2017, closing a stake of 89,884 shares — an estimated $7.63M sold.

Calamos Advisors first reported a position in WST in Q4 2016 and held it in 1 quarter. The position peaked at $7.63M in Q4 2016. 294 funds tracked by Wall St. Rank hold WST as of Q1 2017.

Calamos Advisors reported no remaining West Pharmaceutical position as of Q1 2017 after selling out during the quarter.
Calamos Advisors sold 89,884 West Pharmaceutical shares in Q1 2017, an estimated $7.63M.
Calamos Advisors first reported a position in West Pharmaceutical in Q4 2016 and held it in 1 quarter.
Calamos Advisors's West Pharmaceutical position peaked at $7.63M in Q4 2016.
294 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2017.

Based on Calamos Advisors's 13F filing for Q1 2017, filed 20 Apr 2017.